InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Exclusive Global License to Develop, Manufacture, Commercialize Alzheimer Drug
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on developing novel formulations and drug-delivery systems for traditional therapeutics and psychedelic treatments, has entered into an exclusive global license agreement. The agreement outlines the company’s intentions to further develop, manufacture and commercialize SPC-14, SILO’s Alzheimer’s drug. According to the announcement, the company plans to follow the U.S. Food and Drug Administration’s 505(b)(2) pathway to approval,…